Introduction {#Sec1}
============

Asthma is a complex respiratory disease. It is one of the most common lung disorders, characterized by a chronic airway inflammation \[[@CR1]\]. The airway epithelial cells can produce cytokines and chemokines to initiate immune responses \[[@CR2]\]. Asthma is a T-helper type 2 (Th2)-dependent disease associated to a higher production of interleukin-4 (IL-4) and IL-13, which induces the release of IL-8 from human bronchial epithelial cells \[[@CR3]\].

The IL-8 belongs to the superfamily of CXC chemokines, exerts its effect through two receptors, IL-8 receptor alpha (IL-8 RA, CXCR1) and beta (IL-8 RB, CXCR2). IL-8 is a strong chemotactic cytokine that activates the inflammatory cells by the recruitment of neutrophils, mononuclear phagocytes, mast cells, and T cells \[[@CR4], [@CR5]\]. IL-8 is involved in the initiation of the acute and chronic inflammatory process \[[@CR6]\]. It is implicated in the pathogenesis of several pulmonary diseases like bronchial asthma \[[@CR7]\], Acute Respiratory Distress Syndrome (ARDS) \[[@CR8]\], severe infections caused by respiratory syncytial virus (RSV) \[[@CR9]\], and viral bronchiolitis \[[@CR10]\]. Various reports have also described the capacity of Th2, Th-9, and Th-17 cells to induce the release of proinflammatory cytokines as the IL-8, which contribute to the expansion of neutrophils to the airway epithelial cells of patients with asthma \[[@CR3], [@CR11]--[@CR13]\]. An increased level of IL-8 was observed in Broncho-alveolar fluid (BALF), sputum, and endobronchial biopsies of patients with asthma \[[@CR14], [@CR15]\]. Furthermore, a higher IL-8 serum levels were observed for severe patients with asthma that suggested that IL-8 plays an important role in asthma severity \[[@CR16]\]. Therefore, IL-8 might protect against the development of atopic asthma by the inhibition of IgE production \[[@CR17]\].

Human IL-8 is encoded by a gene located on chromosome 4q13--q21 and composed of four exons, three introns, and a proximal promoter region \[[@CR18]\]. Fifteen IL8 polymorphisms were characterized to date and only two were reported to be associated with altered IL-8 mRNA levels \[[@CR19]\]. The IL-8-251A/T (rs4073) polymorphism located on the promoter region, was reported to be associated with an increased IL-8 level. The IL-8 + 781C/T (rs2227306) located within the first intron, was described to promote gene transcription and regulation \[[@CR20]\]. Recently, genetic association studies showed that these polymorphisms were associated with susceptibility to inflammatory diseases as RSV bronchiolitis, ARDS, lung cancer, and asthma \[[@CR7], [@CR9], [@CR21]--[@CR23]\].

Our data suggest that *IL8* is important in the genetic control of human asthma susceptibility. A recent advance in sequence-specific gene silencing provides a new platform to develop gene-specific drugs for disease management. Then, molecular study of *IL8* gene might contribute to elucidate in part the mechanism of asthma development and facilitate in the future the development of new drugs.

The aim of this study was to analyze the association of rs4073 and rs2227306 polymorphisms with the risk of childhood asthma development. We also investigated the correlation of IL-8 protein and mRNA levels with childhood asthma development and disease severity in the Tunisian population.

Methods {#Sec2}
=======

Study Population {#Sec3}
----------------

A total of 170 asthmatic children were recruited between May 2013 and September 2015, from the department of Pediatric and Respiratory Diseases, Abderrahmane MAMI Hospital of Chest Diseases, Ariana, Tunisia. Asthma diagnosis was established according to GINA recommendations \[[@CR24]\], based on clinical asthma symptoms and lung function test. The classification of asthma severity was determined on the basis of clinical symptoms and lung function according to GINA guidelines. Only patients whose asthma was controlled were retained.

Our population includes 117 patients diagnosed with atopic asthma and 53 without. All patients were classified according to asthma severity into four groups: a mild intermittent (*n* = 2), a mild persistent (*n* = 87), a moderate persistent (*n* = 70), and a severe persistent asthma (*n* = 11).

In addition, we recruited a group of 170 age-matched healthy control children from the emergency department of Tunis children hospital for only pathologies related to accidents of daily life such as fractures and without respiratory or allergy manifestations. All controls were free of any infectious symptoms. The inclusion criteria for the control group were as follows: no symptoms or history of asthma, of other pulmonary diseases, of allergy, and of any chronic disease. Written informed consent was obtained from parents of participating children. All data and sample collections for this study were approved by the local ethics committee (Table [1](#Tab1){ref-type="table"}).Table 1Clinical characteristics of the study populationCharacteristicsPatients with Asthma *n* (%)Healthy individuals *n* (%)Number of subjects170170Age Mean (range)9.1 (2--16)9.5 (4--15)Categories 0--11 years (pediatric children)141 (82.94)134 (78.82) 12--16 years (adolescent)29 (17.05)36 (21.17)Sex Females (girls)61 (36)72 (42) Males (boys)109 (64)98 (58)Atopic status Atopic117 (68.82)-- Non-atopic53 (31.17)--IgE (mean ± SD) \> 200 U/ml^−1^40 (81.63)-- ≤ 200 U/ml^−1^9 (18.36)--Smoke exposure Passive59 (38.06)-- No smoking96 (61.63)--Severity Mild intermittent2 (1.17)-- Mild persistant87 (51.17)-- Moderate persistant70 (41.17)-- Severe persistant11 (6.47)--

All information on tobacco exposure (passive smoking or second-hand smoke, or environmental tobacco smoke) used in this analysis was collected at baseline only for patients. We did not obtain total information from healthy subject parents (the data were missing in more than 20% of patients for tobacco smoking habits in the control group).

The classification of passive and no smoker was based on the information on the active smoking habits status for parent who was never, current, or former smokers. Questions on exposure to passive smoking related to each of the following: "the age at which they started smoking, the number of cigarettes smoked per day and the duration of smoking in years at home and at work." Among former smokers, age at quitting smoking was also collected.

Estimation of Human IL-8 Serum Levels {#Sec4}
-------------------------------------

For the serum preparation, we collect 5 ml of venous blood in a plain tube without anticoagulant and then allowed to clot for about 4 h at room temperature. The serum was separated by centrifugation (1300×*g*, for 15 min), then was taken and stored at − 80 °C until use. The determination of the IL-8 serum levels was performed in duplicate using a commercially available IL-8 Human ELISA (enzyme linked immunosorbent assay) Kit (R&D Systems, Minneapolis, MN, US) with the use of an ELx 800 Automated Microplate Reader, Bio-Tek Instruments (Winooski, VT). The IL-8 serum level data are expressed as mean ± standard error of the mean (SD). A *P* value \< 0.05 was accepted as significant.

Determination of Human IL-8 mRNA Levels {#Sec5}
---------------------------------------

The determination of IL-8 mRNA levels of expression was performed by the real-time quantitative reverse transcription-polymerase chain reaction *(*qRT-*PCR*) as we previously reported \[[@CR25]\]. The mRNA was extracted from peripheral blood mononuclear cells (PBMCs) using TRIZOL^®^ reagent (Invitrogen) according to the manufacturer's instructions. Complementary DNA (cDNA) samples were synthesized using random hexamer primers and RNase H-reverse transcriptase (Fermentas). The qRT-*PCR* was done in a 25 μl reaction using an Applied Biosystems system (*AB*, Foster City, CA). The reaction systems include 15 μg/μl (2.5 μl) of cDNA template, 10 μM of each forward and reverse primers set and the appropriate dilution of SYBR Green mix (QIAGEN, Germany), and the adequate volume of distilled water (Gibco).

The β-actin mRNA (internal control) was quantified in the same way as the IL-8 mRNA, using the forward and reverse primers 5′-ATGACTTCCAAGCTGGCCGT-3′ and 5′-CCTCTTCAAAAACTTCTCCACACC-3′, respectively, and using the probes: 5′-CAAACATGATCTGGGTCATCTTCTC-3′ and 5′-GCTCGTC GTCGACAACGGCTC-3′.

The qRT-*PCR* detection system was used for amplification and the employed cycling program was as follows: Initial denaturation step at 94 °C for 2 min; then 40 cycles of a second denaturation step at 94 °C for 15 s; an annealing step at 59 °C for 45 s, and an extension step at 72 °C for 45 s; after that, a final extension at 72 °C for 10 min.

IL-8 Polymorphisms Genotyping {#Sec6}
-----------------------------

Genomic DNA was extracted from peripheral blood leukocytes using the Salting-out procedure as described \[[@CR26]\]. The study of rs4073 and rs2227306 polymorphisms was assessed for 170 patients and 170 controls. The IL-8 SNPs were genotyped using polymerase chain reaction--restriction fragment length polymorphism (PCR--RFLP)-based method.

The following primers \[Forward: CCATCATGATAGCATCTGT; Reverse: CCACAATTTGGT GAATTATTAA\] were used to amplify the 173-bp DNA fragment of the rs4073 polymorphism. The primers \[Forward: CTCTAACTCTTTATATAGGAATT; Reverse: GATTGATTTTATCAACAGGCA\] were used to amplify the 203-bp DNA fragment of the rs2227306 polymorphism \[[@CR9]\]. The PCR reactions were performed in a total volume of 25 μl containing 100 ng genomic DNA, 0.5 μmol/l of each primer, 200 μmol/l of each dNTP, 10× PCR buffer, 2 mmol/l MgCl2, and 2,5 U of DNA Taq polymerase.

The PCR amplification conditions for the rs4073 polymorphism included an initial denaturation step at 94 °C for 5 min, followed by 30 cycles with a second denaturation step at 94 °C for 30 s, an annealing step at 60 °C for 55 s, and an extension step at 72 °C for 60 s, then a final extension step at 72 °C for 8 min. The PCR products were digested with 1 U of the restriction enzyme *Ase*I (Fermentas). The rs4073 A allele was identified by 21- and 152-bp fragments and the T allele by a single 173-bp fragment.

However, the procedure of PCR amplification for the rs2227306 region was as follows: pre-denaturation at 94 °C for 8 min, 35 cycles of denaturing step at 94 °C for 30 s, annealing step at 54 °C for 30 s, extension step at 72 °C for 30 s, and then a final extension at 72 °C for 10 min. The PCR products were digested by 1 U of the restriction enzyme *Eco*RI (MBI Fermentas). The rs2227306 C allele was identified by 19- and 184-bp fragments and the T allele by a single 203-bp fragment. The digested fragments were visualized on an ultraviolet illuminator after separation on a 3% agarose gel stained with 0.1% ethidium bromide.

Statistical Analysis {#Sec7}
--------------------

The genotype frequencies were tested for the deviation from Hardy--Weinberg equilibrium (HWE).

The association analysis was performed using the open Epi Info Version 6 and 7 software based on a standard Chi-squared test. The *P* values smaller than 0.05 were considered significant. The strength of a genetic association is indicated by the odds ratio (OR). The OR and the 95% confidence intervals (CI) were calculated whenever applicable.

The quantitative statistical analysis was performed by Prism V.5 software (GraphPad Software, San Diego, USA). The IL-8 expression levels were analyzed by the *t* test that used to compare the mean values between two groups. The reported *P* values are two tailed and *P* values \< 0.05 were considered significant.

Haploview program version 4.2 was used to calculate the pairwise Linkage Disequilibrium (LD) between the *IL8* SNPs. The Haplotype frequencies and effects were performed using Haploview. The *P* values for the patient--control differences in diplotype distributions were adjusted for multiple tests by Bonferroni correction. Only the allele frequencies of the diplotype \> 1% were included in the analyses, those \< 1% were excluded.

Results {#Sec8}
=======

IL-8 Serum and mRNA Expression Levels {#Sec9}
-------------------------------------

In the current study, we compared the level of IL-8 protein in the serum and mRNA of 170 cases and 170 controls (Fig. [1](#Fig1){ref-type="fig"}). The IL-8 serum levels were significantly higher in patient (48.82 ± 27.36 pg/ml) than in control (10.67 ± 4.62 pg/ml; *P* \< 0.0001) group (Fig. [1](#Fig1){ref-type="fig"}a).Fig. 1IL-8 expression levels in patients with asthma and healthy controls. **a** IL-8 mRNA levels in healthy and the asthmatic children. The IL-8 mRNA levels were significantly higher in patient than in control group (*P* = 0.004); **b** IL-8 serum levels in healthy and the patients with asthma. The IL-8 serum levels were significantly higher in patient (48.82 ± 27.36) than in control (10.67 ± 4.62) group (*P* \< 0.0001)

No significant difference in PBMC composition between patients with asthma and healthy controls was claimed.

We found that the IL-8 serum concentrations were markedly elevated in children with moderate and severe asthma (*n* = 81; 71.55 ± 21.09 pg/ml) than those with mild form (*n* = 89; 28.55 ± 21.14 pg/ml, *P* \< 0.0001) (Fig. [2](#Fig2){ref-type="fig"}a).Fig. 2Relative expression of IL-8 serum and mRNA levels in patient group, according to asthma severity**. a** Relative expression of IL-8 was calculated as indicated in the method section. Box plot indicating significant elevated serum levels of IL-8 in asthmatic children with moderate/severe asthma (*[n]{.ul}* = 81; 71.55 ± 21.09) compared to children with mild asthma (*n* = 89; 28.55 ± 21.14, *P* \< 0.0001). **b** Relative expression of IL-8 mRNA was calculated as indicated in the method section. Box plot indicating significant elevated IL-8 mRNA levels in asthmatic children with moderate/severe asthma (*n* = 81) compared to those with mild asthma (*n* = 89; *P* = 0.0301)

We also reported in Fig. [1](#Fig1){ref-type="fig"}b, a significantly higher IL-8 mRNA levels in patients than in controls (*P* = 0.004). *IL*-*8* mRNA levels were further increased in patients with moderate-to-severe asthma compared to mild asthma group (*P* = 0.025) (Fig. [2](#Fig2){ref-type="fig"}b).

However, the IL-8 mRNA expression and the distribution of protein levels, according to different IL-8 genotypes for both polymorphisms did not differ significantly in the asthmatic group (Supplementary Fig. 1).

Genotype Analysis of IL-8 Gene {#Sec10}
------------------------------

The distribution of rs4073 and rs2227306 genotype frequencies for healthy controls and patients with asthma was in agreement with HWE (data not shown).

We observed a significant difference in the genotype and allele distributions of rs4073 and rs2227306 polymorphisms between asthmatic and healthy children (Table [2](#Tab2){ref-type="table"}).Table 2Frequency of alleles and distribution of genotypes of *IL8* polymorphisms in asthmatic and control subjectsIL-8 SNPsGenotypeAllelesPopulation*χ* ^2^OR (95% CI)*P* valueAsthmatics *N* = 170(%)Controls *N* = 170(%)rs407312.36**0.002**AA13 (7.64)31 (18.23)1.00^a^AT70 (41.17)78 (45.88)2.14 (0.98--4.71)0.055TT87 (51.17)61 (35.88)3.40 (1.56--7.51)**0.001**A96 (28.23)140 (41.17)1.00^b^T244 (71.76)200 (58.82)1.78 (1.28--2.48)**0.0005**rs22273066.64**0.036**TT12 (7.06)27 (15.88)1.00^a^CT73 (42.94)69 (40.60)2.38 (1.06--5.44)**0.035**CC85 (50)74 (43.52)2.58 (1.16--5.85)**0.018**T97 (28.53)123 (36.18)1.00^a^C243 (71.47)217 (63.82)1.42 (1.01--1.99)**0.040**Bold number indicates significant association*OR* odds ratio, *n* number^a^Reference

For the rs4073, the homozygous TT genotype was more frequent in asthmatic than in control groups (*P* = 0.002). The presence of this genotype was significantly associated with an increased asthma risk (OR 1.78, 95% CI 1.28--2.48). Then, the presence of the rs4073 T allele is considered as a risk factor for asthma development.

The allele and genotype frequencies of rs2227306 were also significantly different between case and control groups, which suggest that the rs2227306 was associated with asthma susceptibility. Our results indicated that the subjects carrying CC or CT genotypes were more exposed to develop asthma compared to those carrying the TT genotype (OR \> 2; *P* = 0.036).

We also analyzed the association of these polymorphisms with atopy. The frequency of the rs4073 TT and rs2227306 CC genotypes differed significantly between children with atopic asthma and healthy controls (*P* = 0.005 and *P* = 0.02, respectively). The presence of the rs4073 TT (OR 1.82, 95% CI 1.25--2.65) or the rs2227306 CC (OR 1.68, 95% CI 1.14--2.47) genotypes was associated with an increased risk to develop atopic asthma (Table [3](#Tab3){ref-type="table"}).Table 3Genotypes distribution and alleles frequencies of *IL8* polymorphisms according to atopic statusAtopyIL-8 SNPsGenotypesAllelesPopulation*χ* ^2^*P*OR (95%CI)Patients *N* (%)Controls *N* (%)Atopic asthmars407310.350.005AA9 (7.69)31 (18.23)1.00^a^AT47 (40.17)78 (45.88)2.450.112.08 (0.85--5.17)TT61 (52.13)61 (35.88)8.200.0043.44 (1.42--8.55)A65 (27.77)140 (41.17)1.00^b^T169 (72.22)200 (58.82)10.260.0011.82 (1.25--2.65)rs22273067.270.02TT8 (6.84)27 (15.88)1.00^a^CT43 (36.75)69 (40.60)2.200.132.10 (0.82--5.56)CC66 (56.41)74 (43.52)5.81**0.0153.01 (1.20--7.78)**T59 (62.6)123 (36.18)1.00^b^C175 (37.4)217 (63.82)7.19**0.0071.68 (1.14--2.47)**Non-atopic asthmars40734.790.09AA4 (7.54)31 (18.23)1.00^a^AT23 (43.39)78 (45.88)1.450.222.29 (0.67--8.53)TT26 (49.05)61 (35.88)3.640.053.30 (0.97--12.30)A31 (29.24)140 (41.17)1.00^b^T75 (70.75)200 (58.82)4.37**0.031.69 (1.03--2.79)**rs22273064.930.08TT4 (7.55)27 (15.88)1.00^a^CT30 (56.60)69 (40.60)2.850.092.93 (0.87--10.88)CC19 (35.85)74 (43.52)0.440.501.73 (0.49--6.65)T38 (35.85)123 (36.18)1.00^a^C68 (64.15)217 (63.82)0.000.951.01 (0.63--1.64)Bold number indicates significant association*OR* odds ratio, *n* number^a^Reference

Subject with at least one copy of rs4073 T allele had more risk to be diagnosed with asthma disease at an advanced stage (*P* = 0.02; OR 3.68, 95% CI 1.12--13.29) (Supplementary Table 1). Then, the rs4073 T allele is considered as a risk factor for asthma severity in Tunisian children.

Haplotype Frequencies of IL-8 Gene {#Sec11}
----------------------------------

LD test between *IL*-*8* polymorphisms was estimated by the value of D' (0.151). The most frequent diplotype in our population was TC (42.6%), but no significant difference was shown between patients and controls (*P* \> 0.05). Therefore, the frequency of the rare diplotype AT was significantly associated with low asthma childhood risk in our population *(P* ~C~ \< 0.0004) (Supplementary Table 2).

Discussion {#Sec12}
==========

Our results indicated an elevated IL-8 serum and mRNA levels in the Tunisian asthmatic children and particularly for the subjects with moderate/severe asthma. The excessive release of IL-8 in asthmatic group, observed in our study was consistent with many previous findings \[[@CR27], [@CR28]\]. In the same way, different studies revealed a positive association between the increased neutrophil count and asthma severity \[[@CR29], [@CR30]\]. Then, the reason of the increase in IL-8 levels may be due to the association of the IL-8 to neutrophil recruitment in the lung injury. In fact, human bronchial epithelial cells, fibroblasts, and airway smooth muscle cells recruit neutrophils into the airways by the release of IL-8 and/or other chemokines \[[@CR13], [@CR31]\]. IL-8 might participate extensively in the development of airway inflammation and hyperresponsiveness in asthma \[[@CR27]\] and might be used as a biomarker for disease evolution and severity.

In the present case--control study, we also analyzed the association of two *IL8* variants with the childhood asthma susceptibility. Our findings suggested that the rs4073 and rs2227306 were strongly associated with an increased childhood asthma risk. These results indicated that the expression of *IL*-*8* genetic polymorphisms could contribute to the pathogenesis of childhood asthma.

Our results represent a replication of previous Heinzmann et al. \[[@CR7]\] findings, in the German asthmatic children. The presence of rs4073 was also associated with the risk to develop RSV bronchiolitis \[[@CR32]\], acute pancreatitis \[[@CR33], [@CR34]\], atrophic gastritis \[[@CR35]\], and Behcet's disease \[[@CR36]\]. In contrast, many other studies did not find any significant association with the polymorphism rs4073 and the risk of chronic obstructive pulmonary disease (COPD) or lung cancer development \[[@CR37], [@CR38]\]. Discrepancies in ethnicities, sample size, and genetic background may have caused the difference in the results of different studies.

Our data indicated a significant association between the rs4073 T allele and the childhood asthma atopy and severity. In fact, previous study indicated that the presence of the rs4073 T was associated with an increased IL-8 levels in the bronchioles contributing to a higher local pulmonary inflammation and then to asthma severity \[[@CR39]\].

Genetic polymorphisms may have important functional consequences. These variations are able to influence the expression or the activity of the resulting protein. It has been reported that the two polymorphisms rs4073 and rs2227306 influenced the transcriptional activity of the *IL8*. Firstly, the expression levels of IL-8 (mRNA and protein) might be influenced by other factors than the only presence of IL-8 variants and the expression of these SNPs might have other effects like the alteration of the expression of a more distant gene in particular SNP situated in the promoter region. Secondly, when SNPs were not studied within the exact haplotype blocks (some SNPs in the same region are in LD with others SNPs), we cannot conclude about the real effect of IL-8 SNPs on the expression of IL-8.

The rs4073 is the most important polymorphism and it is located in the transcription start site \[[@CR40]\]. Both in vitro and in vivo studies indicated that this polymorphism increases the production of IL-8. Lee et al. \[[@CR39]\] have described that the rs4073 T allele possessed a transcriptional activity twofold to fivefold stronger than the rs4073 A allele, which contributed to the high IL--8 amount as described. Additionally, it has been shown that the *IL8* promoter DNA sequence around the position--251 was conformed to the binding motif of C/EBP (CCAAT/enhancer binding protein) \[[@CR41], [@CR42]\]. Then, this functional effect might be related to the fact that the nuclear factors such as C/EBP and GATA bind with high affinity to the IL-8 transcription regulatory sites in the presence of the T allele. However, experimental results suggest that the differences in IL-8 expression are not linked directly to the rs4073 polymorphism \[[@CR36]\]. Therefore, other SNPs could be implicated in the transcriptional and translational activities.

For the rs2227306, our findings were consistent to report results in asthma and rheumatoid arthritis \[[@CR7], [@CR43]\]. In fact, it has been reported that the rs2227306 located in *IL8* intron 1, promotes the regulation of gene transcription by a CAAT (cytosine--cytosine--adenosine--adenosine--thymidine) box that locates downstream of rs2227306. Hacking et al. \[[@CR19]\] observed that C/EBP β preferentially bound in the presence of the rs2227306 T allele in respiratory epithelial cells. C/EBP β has an important role in the regulation of inflammation, and its binding to the regulatory region in the *IL8* gene increases significantly the transcription \[[@CR20], [@CR44]\].

In our study, the frequency of the less frequent haplotype AT was significantly associated with low asthma childhood risk in our population *(P* \< 0.0004). In contrast, this haplotype is the more transmitted in patients with bronchiolite, then it represented a significant association with susceptibility to bronchiolitis \[[@CR40]\].

In conclusion, to our knowledge, this is the first study in the association of rs4073 and rs2227306 polymorphisms with childhood asthma risk in the Tunisian population. Our data confirmed the inflammatory role of IL-8, which could be used as a marker for asthma childhood severity. Further investigation on the *IL8* gene variants and their biological functions is also needed.
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